TanyaSiddiqiMD
Hematology • Irvine, CAHematologic Oncology
Medical Director of Lymphoma, COH-OC and Director, CLL Program
Dr. Siddiqi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1000 FivePoint
Irvine, CA 92618Phone+1 949-999-8979Fax+1 626-389-3061- Is this information wrong?
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Aga Khan Medical CollegeClass of 2000
University of ConnecticutResidency, Internal Medicine
Certifications & Licensure
CA State Medical License 2009 - 2025
MA State Medical License 2006 - 2011- American Board of Internal Medicine Hematology
Clinical Trials
- A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
- Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Start of enrollment: 2012 Apr 16
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
- Join now to see all
Publications & Presentations
PubMed
- Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.Constantine S Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G Owen, Paula Marlton, Björn E Wahlin, Ramón García-Sanz, Helen McCart...> ;Blood Advances. 2024 Apr 9
- Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.Adam S Kittai, David Bond, Ying Huang, Seema A Bhat, Emily Blyth, John C Byrd, Julio C Chavez, Matthew S Davids, Jamie P Dela Cruz, Mark R Dowling, Caitlyn Duffy, Carr...> ;Journal of Clinical Oncology. 2024 Mar 29
- 17 citationsLisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.Tanya Siddiqi, David G Maloney, Saad S Kenderian, Danielle M Brander, Kathleen Dorritie, Jacob Soumerai, Peter A Riedell, Nirav N Shah, Rajneesh Nath, Bita Fakhri, Deb...> ;Lancet. 2023 Aug 19
- Join now to see all
Abstracts/Posters
- Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...Tanya Siddiqi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...Tanya Siddiqi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lympho...Tanya Siddiqi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patient...2019 ASCO Annual Meeting - 6/1/2019
- Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Other
- Contraception for women with inherited thrombophiliasSiddiqi T, Bauer KA, Barbieri RL
http://www.uptodate.com/contents/contraception-for-women-with-inherited-thrombophilias
UpToDate, Wolters Kluwer Health - 2013-04-01
Press Mentions
Survival Similar in CLL Without Undetectable MRD Regardless of Continued Therapy TypeApril 26th, 2023- City of Hope Scientists Present Potential New Treatments for Chronic Lymphocytic Leukemia, Myelofibrosis and Other Diseases at American Association of Cancer Research (AACR) Annual MeetingApril 17th, 2023
- YOUR HEALTH: CAR T Cells Save Chuck from Non-Hodgkin LymphomaFebruary 28th, 2023
- Join now to see all
Hospital Affiliations
City of Hope Comprehensive Cancer CenterDuarte, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
